Patent ID: 11905564
Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Field: Biotechnology (Chemistry)
Classification: CPC C | IPC C

Claim 5:
6. A method of determining if a test patient has stage 1, stage 2, or stage 3 cervical intraepithelial neoplasia, cervical cancer, HPV-associated pre-cancer, or HPV-associated cancer, the method comprising
contacting the sample containing cells from the test patient's cervix with one or more first polynucleotides, and
determining an expression level of a lnc-FANCI-2 polynucleotide in the sample by detecting the level of hybridization of the one or more first polynucleotides to the lnc-FANCI-2 polynucleotide,
correlating the expression level of the lnc-FANCI-2 polynucleotide in the sample to a reference expression level of the lnc-FANCI-2 polynucleotide in a reference sample that is
a control sample from a patient or patients with no evidence of cervical cancer,
a control sample from a cervical cancer patient or patients,
a control sample from a patient or patients with stage 1, stage 2, or stage 3 cervical intraepithelial neoplasia,
a control sample from a patient or patients with no evidence of HPV-associated pre-cancer or HPV-associated cancer,
a control sample from a patient or patients with HPV-associated pre-cancer, or
a control sample from a patient or patients with HPV-associated cancer; and

determining, based on said correlation, whether the test patient has cervical cancer, stage 1, stage 2, or stage 3 cervical intraepithelial neoplasia, HPV-associated pre-cancer, or HPV-associated cancer,, wherein the one or more first polynucleotides are SEQ ID NOs: 78, 79 and 80.